HOME >> MEDICINE >> NEWS
GroPep completes final milestone of the path malaria vaccine initiative

Adelaide biotechnology company GroPep has completed the manufacture of two vaccine antigens as part of the project funded by the international PATH Malaria Vaccine Initiative (MVI).

GroPep will supply these vaccine antigens to the MVI for formulation and subsequent use in human clinical trials - expected to start in 2007.

Listed biopharmaceutical company GroPep Limited (ASX :GRO) announced today that it had successfully completed the second and final milestone of its agreement with the PATH Malaria Vaccine Initiative to manufacture malaria vaccine candidates for testing in human clinical trials.

GroPep reported the successful completion to Milestone 1 of the vaccine project in September 2003, developing scalable manufacturing processes for two malaria vaccine candidates.

Milestone 2 required scale-up of production and manufacturing to appropriate quality standards to enable the potential malaria vaccines to be tested in human safety trials. A sufficient quantity of each vaccine antigen has been manufactured.

PATH is an international, non-profit organisation that creates sustainable, culturally relevant solutions allowing global communities to break long-standing cycles of poor health. The Malaria Vaccine Initiative's (MVI) mission is to accelerate the development of malarial vaccines for the developing world. Malaria kills 7000 people each week and there is no vaccine.

MVI Director, Dr Melinda Moree congratulated GroPep on completing this important project milestone. "GroPep has made an important contribution to the quest to develop a vaccine against malaria."

GroPep's CEO, Bob Finder said that the manufacturing project had provided GroPep with a number of technical challenges that had been successfully met.

"As a Company, we are pleased to have successfully completed our part of the project, which may ultimately reduce the impact of this disease on millions of people worldwide," he said.
'"/>

Contact: Tony Mitchell
investorrelations@gropep.com.au
61-883-547-700
Research Australia
19-Dec-2005


Page: 1 2

Related medicine news :

1. GroPep awarded key patent for infertility treatment in Europe
2. GroPep starts Phase 1 infertility trial
3. GroPep to pursue promising asthma drug following preclinical study results
4. GroPep licenses technology to TGR BioSciences
5. GroPep news: Key psoriasis patent granted in Japan and new asthma patent filed for GroPep drug
6. Asthmatx completes enrollment in pivotal study of bronchial thermoplasty
7. Acrux completes enrollment in key phase 2 trial
8. MacroChem completes patient enrollment for Phase II trial of EcoNail for treatment of onychomycosis
9. Im a Kid Too project completes first phase
10. 6 finalists compete for achievement in operations research
11. Heart Rhythm Society publishes final recommendations for heart patients

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/15/2018)... ... ... Today David Hyde Apparel debuts the first, fully effective sweat-proof and stain-resistant ... for confidence and comfort year-round, the new shirt leverages a patent-pending, double-sided fabric to ... humid of climates. , The brainchild of two recent University of Central Florida graduates ...
(Date:8/14/2018)... ... August 14, 2018 , ... Gastro Health, LLC ... roles for healthcare executives Simon Frisch and Chris Weinstein, who have been appointed ... their roles at a time of tremendous growth for the group, which has ...
(Date:8/11/2018)... ... ... Dr. Siavash Eftekhari, Oral and Maxillofacial Surgeon at Monarch Dental® in Grapevine, ... deliver dental care in impoverished communities. Along with a team of fellow Smile ... help deliver care to over 550 individuals in need. , This outreach was hosted ...
(Date:8/9/2018)... ... August 09, 2018 , ... ... implants have ruptured, according to cross-referenced data from The American Society of Plastic ... implant rupture rates monitored by the FDA. As an MRI is recommended by ...
(Date:8/9/2018)... ... August 09, 2018 , ... Thanks ... and the company’s independent distributors, customers, and employees, the newly established Isagenix ... exceeding the $2 million goal. 100 percent of the donations will fund grants ...
Breaking Medicine News(10 mins):
(Date:8/2/2018)... ... August 02, 2018 , ... UMD Professor Utpal Pal leads a team ... years from the National Institute of Allergy and Infectious Diseases (NIAID), part of the ... immune responses of ticks that contribute to the spread of major diseases like Lyme ...
(Date:8/2/2018)... ... 2018 , ... As kids begin heading back to school, ... include concerns with speaking, listening, reading, writing, and social interactions. Children may be ... parents should know, according to the American Speech-Language-Hearing Association (ASHA): , How Speech-Language ...
(Date:8/2/2018)... ... August 02, 2018 , ... Although there is a ... it is contradictory and based on a generalized “best practices” approach. But now doctors ... the right combination for optimal health. , Technology exists to help people find the ...
Breaking Medicine Technology:
Cached News: